Houston female-health focused tech company makes 2 key acquisitions

making moves

FemTec Health has acquired two companies — a women's reproductive platform and a nutrition platform. Image via avawomen.com

Last month, a Houston-based, tech-enabled health and beauty sciences company made two acquisitions of startups in the femtech space.

FemTec Health, creator of the Awesome Woman comprehensive health care subscription platform, has acquired Ava AG — a women's reproductive digital diagnostics and therapeutics company — and Nutrimedy — a clinical nutrition platform.

Ava, founded by Lea von Bidder in Zurich in 2014, uses artificial intelligence and clinical trials-backed science to help women conceive faster. Per a news release, the FDA-cleared technology has helped over 70,000 women get pregnant.

"What Lea and the Ava team have built is truly innovative. We are excited to add the leader in reproductive health to our portfolio and onto our team," says Dr. Kimon Angelides, FemTec Health founder and CEO, in the July 19 release. "From fertility to contraception, pregnancy support, menopause management, and personalized health insights, Ava's technology is a great addition to make it even easier for women within the FemTec Health platform to take control of their health, all while keeping their data and personal health information one hundred percent private and secure."

FemTec Health's Awesome Woman platform will integrate Ava's technology, adding reproductive health to its list of female-focused health care services which includes vaginal health, hormone balance, sexual wellness, and beauty.

"Ava's vision has always been to be a companion to women along every stage of their lives. With Ava's female health AI integrated into FemTec's care platform, women will finally have access to a fully continuous health journey," says von Bidder in the release. "We are excited to join FemTec in building continuous support for women from puberty to menopause."

Last week, FemTec announced the acquisition of Nutrimedy, a HIPAA-compliant digital health platform founded by Karolina Starczak in Boston in 2016. With the acquisition, Awesome Women members will have access to Nutrimedy's guided nutritional support.

"For many health conditions, nutrition is a key but often neglected component," says Angelides, in the July 25 news release. "Adding Nutrimedy's robust, evidence-based clinical nutrition platform to the Awesome Woman program will be a gamechanger for our subscribers. Whether it's to optimize pregnancy planning, manage menopause symptoms, or for general wellness and prevention, research shows women are seeking personalized, science-backed nutritional support that's easy to use and that they can trust."

With its AI-powered platform, users can access real-time food recommendations and photo food logging. Nutrimedy empowers those suffering from chronic conditions and disruptive food allergies and sensitivities, to make informed dietary decisions in the moment.

"Nutrimedy was started with the mission to improve access to nutrition in healthcare and make it significantly more personalized and actionable in our hectic daily routines," says Starczak in the release. "Within the field of nutrition, conflicting and confusing misinformation is pervasive and prevents most people from making the best decision for their individual health."

Last fall, FemTec Health emerged from stealth with $35 million in fresh VC investment. The company has also acquired Birchbox, Mira Beauty, and Liquid Grids over the past year.

Angelides, a Houstonian, previously told InnovationMap that he was driven to found FemTech Health because there was no holistic platform focused on every phase of women's health.

"Women don't really have a program that's designed for them," Angelides says on the Houston Innovators Podcast. "We embarked in terms of building a platform and a company that would be a single destination for women — one that's not age specific but built around journeys."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

UH lands $11.8M for first-of-its-kind early language development study

speech funding

Researchers at the University of Houston have secured an $11.8 million grant from the National Institutes of Health to conduct a first-of-its-kind study of early language development.

Led by Elena Grigorenko, the Hugh Roy and Lillie Cranz Cullen Distinguished Professor of Psychology, and research professor Jack Fletcher, the study will follow 3,600 children aged 18 to 24 months to uncover how language skills develop at this critical stage and why some children experience delays that can influence later growth.

The NIH funding will also support the development of the new national Clinical Research Center on Developmental Language Disorders at UH, which aims to bring experts from psychology, education, health and measurement sciences to study how children learn language.

“This will be the first national study to estimate how common late talking is using a large, representative sample of Houston toddlers,” Grigorenko said in a news release. “By following these children as they grow, we hope to better understand the developmental pathways that can lead to conditions such as developmental language disorder and autism.”

UH’s team will partner with the pediatric clinic network at Texas Children’s Hospital, where children will be screened for early language development, allowing researchers to identify those who show signs of delayed speech. Next, researchers will follow the cohort through early childhood to examine how language abilities evolve and how early delays may lead to later challenges.

The Clinical Research Center on Developmental Language Disorders will be the 14th national research center established at UH, and will include researchers from multiple UH departments, as well as partners at Baylor College of Medicine and the Texas Center for Learning Disorders.

“This level of investment from the National Institutes of Health reflects the significance of this work to address a complex challenge affecting children, families and communities,” Claudia Neuhauser, vice president for research at UH, said in a news release. “By bringing together experts from multiple disciplines and partnering with major health systems across the region, the project reflects our commitment to advancing discoveries that impact our community.”

Rice Alliance names Houston healthtech exec as first head of platform

new hire

The Rice Alliance for Technology and Entrepreneurship has named its first head of platform.

Houston entrepreneur Laura Neder stepped into the newly created role last month, according to an email from Rice Alliance. Neder will focus on building and growing Houston’s Venture Advantage Platform.

The emerging platform, which is being promoted by Rice Alliance and the Ion, aims to connect founders with the "people, capital and expertise they need to scale."

"I’ve spent a lot of time thinking about what it takes to make an innovation ecosystem more navigable, more connected, and more useful for founders," Neder said in a LinkedIn post. "I’m grateful for the opportunity to do that work at Rice Alliance, alongside a team with a long history of supporting entrepreneurship and innovation."

"Houston has the talent, institutions, and industry base to create real advantage for founders," she added. "I’m looking forward to listening, learning, and building stronger pathways across the ecosystem."

Neder most recently served as CEO of Houston-based Careset, where she helped bring the Medicare data startup to commercialization. Prior to that, Neder served as COO of Houston-based telemedicine startup 2nd.MD, which was acquired for $460 million by Accolade in 2021.

"Laura brings a rare combination of founder empathy, operational experience and ecosystem leadership," Rice Alliance shared.

Neder and Rice Alliance also shared that the organization is hiring developers to design the new Venture Advantage Platform. Learn more here.

Elon Musk's SpaceX files initial paperwork to sell shares to the public

Incoming IPO

Elon Musk's space exploration company has filed preliminary paperwork to sell shares to the public, according to two sources familiar with the filing, a blockbuster offering that would likely rank as the biggest ever and could make its founder the world's first trillionaire.

A SpaceX IPO promises to be one of the biggest Wall Street events of the year, with several investment banks lining up to help raise tens of billions to fund Musk's ambitions to set up a base on the moon, put datacenters the size of several football fields in orbit and possibly one day send a man to Mars.

The sources spoke on condition of anonymity because they were not authorized to talk publicly about the confidential registration with the Securities and Exchange Commission.

SpaceX did not respond immediately to a request for comment.

Exactly how much SpaceX plans to raise has not been disclosed but the figure is reportedly as much as $75 billion. At that level, the offering would easily eclipse the $29 billion that Saudi Aramco raised in its IPO in 2019.

The offering, coming possibly in June, could value all the shares of SpaceX at $1.5 trillion, nearly double what the company was valued in December when some minority owners sold their stakes, according to research firm Pitchbook, before an acquisition that increased its size.

Musk owns 42% of the SpaceX now, according to Pitchbook, though that figure will change with the IPO when new owners are issued shares. In any case, he is likely to pierce the trillion dollar mark because he is already close. Forbes magazine estimates Musk's net worth at roughly $823 billion.

In addition to making reusable rockets to hurl astronauts and hardware into orbit, SpaceX owns Starlink, the world’s largest satellite communications company. The company also recently brought under its roof two other Musk businesses, social media platform X, formerly Twitter, and artificial intelligence business, xAI, in a controversial transaction because both the seller and the buyer were controlled by him.

SpaceX has become the biggest commercial launch company in its industry, responsible for sending payloads into orbit for customers across the globe, but has also benefited from big taxpayer spending. That has raised conflicts of interest issues given that Musk was the biggest donor to President Donald Trump's campaign and is still a big backer.

In the past five years, SpaceX won $6 billion in contracts from NASA, the Defense Department and other U.S. government agencies, according to USAspending.gov.

Among current SpaceX owners is Donald Trump Jr, the president's oldest son. He owns a shares through 1789 Capital. That venture capital firm made him a partner shortly after his father won the presidency for a second time and has been buying up federal contractors seeking to win taxpayer money ever since.

The White House and Trump himself have repeatedly denied there are any conflicts of interest between his role as president and his family's businesses.

View All Listings